On Friday, Shares of Charles Schwab Corp (NYSE:SCHW), gained 0.09% to $34.79.
Schwab, declared the launch of SchwabSafe, an online resource with perspectives and tips on cyber security for clients. The first investment services firm to provide a Security Guarantee that covers 100% of any losses in any Schwab accounts due to unauthorized activity (launched nearly 10 years ago), Schwab continues to expand its resources for online security and fraud prevention to comprise educational programs such as SchwabSafe, client seminars and live consultations, and its numerous behind-the-scenes methods of authenticating clients to safeguard client accounts against unauthorized activity and fraud.
“It has always been our practice to make clients whole in cases of unauthorized account activity. The security guarantee turned that historic practice into a public promise 10-years ago,” said Jim McGuire, chief information officer at Schwab. “While a guarantee provides a safety net, everyone has a role to play in security protection. We provide multiple behind-the-scenes methods of authenticating clients and we encourage our clients to learn as much as they can about safe online security practices – not just for their interaction with us, but in all aspects of online commerce,” McGuire said.
The Charles Schwab Corporation, through its auxiliaries, provides wealth administration, securities brokerage, banking, money administration, and financial advisory services. The company operates through two segments, Investor Services and Advisor Services.
Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN), inclined 0.02% to $204.30, during its last trading session.
Alexion Pharmaceuticals, declared that Japan’s Ministry of Health, Labour and Welfare (MHLW) approved the Company’s New Drug Application (NDA) for the use of Strensiq® (asfotase alfa) as a treatment for patients in Japan with hypophosphatasia (HPP), a life-threatening, ultra-rare metabolic disorder. Strensiq, a bone-targeted enzyme replacement therapy, is the first therapy approved in Japan for the treatment of patients with HPP. Alexion anticipates that initial patients with HPP in Japan will start commercial treatment with Strensiq by late Q3 2015.
“The rapid approval of the Strensiq NDA in Japan underscores the devastating nature of HPP and the life-transforming impact that Strensiq can provide to Japanese patients living with HPP,” said David Hallal, Chief Executive Officer of Alexion. “We are delighted that this regulatory approval in Japan marks the first treatment option for patients with HPP, and we look forward to urgently working with the healthcare authorities to make Strensiq accessible to Japanese patients who can benefit from this therapy. I would also like to thank the investigators, patients, and their families in Japan who take partd in the clinical trial that led to this approval.”
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. It offers Soliris (eculizumab), a therapeutic product to treat paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease.
Finally, YY Inc (ADR) (NASDAQ:YY), ended its last trade with 2.19% gain, and closed at $59.81.
YY Inc., declared that in response to the formerly declared preliminary non-binding proposal contained in a letter dated July 9, 2015 that the Company’s board of directors received from Mr. Jun Lei, Chairman of the Board, and Mr. David Xueling Li, director and Chief Executive Officer of YY proposing a “going-private” transaction to acquire all of the outstanding ordinary shares of YY not already beneficially owned by the Buyer Group, the Board has formed a special committee of independent and disinterested directors to review and evaluate the Proposal.
The Special Committee is composed of Mr. Peter Andrew Schloss, Mr. David Tang, and Mr. Peng Tsing Ong, who are independent directors of the Company and are unassociated with the Proposal. Mr. Schloss will be the chairman of the Special Committee. The Board also authorized the Special Committee to, and anticipates that the Special Committee will, retain independent advisors, counting independent financial and legal advisors, to assist it in the process of reviewing and evaluating the Proposal.
YY Inc., through its auxiliaries, operates an online social platform in the People’s Republic of China. It engages users in real-time online group activities through voice, video, and text on personal computers and mobile devices; and enables users to create and organize groups of various sizes to discover and take part in a range of online activities, counting music shows, online games, dating shows, live games broadcasting, and e-learning.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
